# US 2025/0152585 A1 · Pharmaceutical compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152585 A1
- Document ID: US20250152585A1
- Status: Published application
- Kind: A1
- Application number: 18/838,190
- Filed: 2023-02-14
- Published: 2025-05-15
- Earliest claimed: 2022-02-16
- Assignees: Duke Street Bio Limited
- Applicants: Duke Street Bio Limited
- Inventors: Phillip Martin Cowley; Alan Wise; Christopher Hill
- Web page: https://patentgrep.com/patent/US20250152585A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; R1 and R2 may together form a ring; R3 is independently selected from H and a substituted or unsubstituted organic group; R6 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; Z1 and Z2 are independently selected from C and N; and L comprises an organic group as defined herein.

## Claims

### Claim 1

A poly (ADP-ribose) polymerase-1 (PARP1) inhibitor compound comprising a structure selected from:
wherein:
the dotted lines indicate that the ring D may comprise single bonds, or a combination of both single and double bonds, and may be aliphatic or aromatic;
each X4 is independently selected from C, N, O and S;
each R11 is independently selected from H and a substituted or unsubstituted organic group;
R3 is selected from H and a substituted or unsubstituted organic group;
R6 is absent or selected from H, halogen, C1 to C3 alkyl, C1 to C3 haloalkyl, C1 to C3 alcohol or C1 to C3 aminoalkyl;
Z1 is selected from C and N; and
L is a group having the following structure:
wherein,
n is a number selected from 0, 1, 2, 3, 4, 5 and 6; and
m is a number selected from 0, 1, 2, 3, 4, 5 and 6, with the proviso that m+n is a number selected from 2, 3, 4, 5, and 6;
p is a number selected from 0, 1, 2, 3, 4, 5, and 6; and
q is a number selected from 0, 1, 2, 3, 4, 5, and 6, with the proviso that p+q is a number selected from 2, 3, 4, 5, and 6;
r is a number selected from 0, 1, 2, 3, 4, and 5; and
s is a number selected from 0, 1, 2, 3, 4, and 5, with the proviso that r+s is a number selected from 1, 2, 3, 4, and 5;
each X1 is independently selected from C, N, O and S;
each X2 may be the same or different and is independently selected from C, N, O and S;
each X3 is independently selected from C, N, O and S;
X5 is independently selected from C and N;
each X6 is independently selected from C and N;
each R41, R42, R43, and R44 is independently absent, or is selected from H and a substituted or unsubstituted organic group;
R5 is selected from H and a substituted or unsubstituted organic group; and the dotted lines indicate that the ring C comprises single bonds or a combination of both single and double bonds, and is aliphatic or aromatic.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R41, R42, R43, and R44 are each independently selected from H and a group selected from the following groups:
deuterium;
a halogen;
a nitrile group;
a substituted or unsubstituted linear or branched C1-C6 alkyl group;
a substituted or unsubstituted linear or branched C1-C6 alkyl-aryl group;
a substituted or unsubstituted linear or branched C1-C6 halogenated alkyl group;
—NH2 or a substituted or unsubstituted linear or branched primary secondary or tertiary C1-C6 amine group;
a substituted or unsubstituted amino-aryl group;
a substituted or unsubstituted cyclic amine or amido group;
a substituted or unsubstituted cyclic C3-C8 alkyl group;
an —OH group or a substituted or unsubstituted linear or branched C1-C6 alcohol group;
a substituted or unsubstituted linear or branched C1-C6 carboxylic acid group;
a substituted or unsubstituted linear or branched carbonyl group;
a substituted or unsubstituted linear or branched C1-C6 carboxylic acid ester group;
a substituted or unsubstituted linear or branched C1-C6 amide group;
a substituted or unsubstituted linear or branched C1-C7 amino carbonyl group;
a substituted or unsubstituted linear or branched C1-C7 alkoxy or aryloxy group;
a substituted or unsubstituted linear or branched aminoalkoxy group;
a substituted or unsubstituted sulphonyl group;
a substituted or unsubstituted aminosulphonyl group;
a substituted or unsubstituted aromatic group;
a saturated or unsaturated, substituted or unsubstituted, heterocyclic group including an aromatic heterocyclic group and/or a non-aromatic heterocyclic group;
where there are two R groups attached to the same atom, they may together form a group which is double bonded to that atom;
wherein, a pair of R41 groups attached to different atoms may together form a ring with ring A atoms, and/or a pair of R42 groups attached to different atoms may together form a ring with ring B atoms; and
wherein groups R5 and R44 may together form a ring with atoms X6 and X3 of ring C to which they are attached.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein R41, R42, R43 and R44 are each independently selected from H, deuterium, a halogen, a nitrile group, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted linear or branched C1-C6 halogenated alkyl group, a cyclopropyl group, an —OH group or a substituted or unsubstituted linear or branched 01-06 alcohol group, a substituted or unsubstituted linear or branched C1-C7 amino carbonyl group, an —NH2 group or a substituted or unsubstituted C1-C6 amino group and a substituted or unsubstituted C1-C6 alkoxy group;
wherein, when a pair of R41 groups attached to different atoms together forms a ring with ring A atoms, and/or when a pair of R42 groups attached to different atoms together forms a ring with ring B atoms, each of the pair of R41 groups and/or pair of R42 groups independently comprises —CH2— or —CH2CH2—; and wherein when groups R5 and R44 together form a ring with atoms of ring C, R5 and R44 together comprise —CH═CH—CH═CH— or —NH—CO—NH—.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

A compound according to claim 1, wherein ring A of the group L is selected from:

### Claim 9 (depends on 8)

A compound according to claim 8, wherein ring A of the group L is selected from:

### Claim 10 (depends on 1)

A compound according to claim 1, wherein ring C of the group L is selected from:

### Claim 11 (depends on 10)

A compound according to claim 10, wherein ring C of the group L is selected from:

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A compound according to claim 1, wherein the group R5 is selected from H, —F, —Cl, —Br, —I, —CN, —CONR51R51, —NR51COR52, —SO2NR51R51, —NR51SO2R53, —O—CR52R52, —CR52R52NR51R51 and any of the following structures:
wherein, each of R51, R52 and R53 may be the same or different and are independently selected from H and a substituted or unsubstituted organic group.

### Claim at position 12

14-17. (canceled)

### Claim 18 (depends on 1)

A compound according to claim 1, wherein ring B of the group L is selected from

### Claim at position 14

19-24. (canceled)

### Claim 25 (depends on 1)

A compound according to claim 1, wherein the group L is selected from:

### Claim 26 (depends on 1)

A compound according to claim 1, wherein m is selected from 1 or 2, n is selected from 2 or 3, p is selected from 1, 2 or 3 and q is selected from 1 or 2.

### Claim at position 17

27-30. (canceled)

### Claim 31 (depends on 1)

A compound according to claim 1, wherein the group L is selected from:

### Claim 32

(canceled)

### Claim 33 (depends on 1)

A compound according to claim 1, which compound is selected from:

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A compound according to claim 1, which compound is selected from:

### Claim 36 (depends on 1)

A compound according to claim 1, wherein each R11 is independently selected from H, a halogen, a nitrile group, a linear or branched C1-C3 alkyl group, a linear or branched C1-C3 halogenated alkyl group, an —OH group, a linear or branched C1-C3 alcohol group, a halogenated linear or branched C1-C3 alcohol group, —NH2, a linear or branched primary secondary or tertiary C1-C3 amine group, a halogenated linear or branched primary, secondary or tertiary C1-C3 amine group, a linear or branched C1-C3 alkoxy group, a linear or branched C1-C3 halogenated alkoxy group, and/or a pair of R11 groups attached to the same atom forming ═O; and independently, and/or when a pair of R11 groups attached to different atoms together forms a ring with ring D atoms, the pair of R11 groups comprises —CH2CH2CH2—.

### Claim 37

(canceled)

### Claim 38 (depends on 36)

A compound according to claim 36, which compound is selected from:

### Claim at position 26

39-42. (canceled)

### Claim 43 (depends on 1)

A compound according to claim 1, wherein R3 is H.

### Claim 44

(canceled)

### Claim 45 (depends on 1)

A compound for use in medicine according to claim 1, which compound is selected from:

### Claim at position 30

46-54. (canceled)

### Claim 55 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, a pharmaceutically-acceptable additive and/or excipient, and a further agent for treating cancer.

### Claim at position 32

56-57. (canceled)

### Claim 58 (depends on 1)

A method of treating a disease and/or a condition and/or a disorder, which method comprises administering to a patient a compound of claim 1.

### Claim at position 34

59-69. (canceled)
